Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 19, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 4,552 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 15, 2005, and was advised to the Company on September 16, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Key Facts for Investor Verification
- Transaction Date: September 15, 2005.
- Shares Transferred: 4,552 Ordinary Shares.
- Source: Abacus (GSK) Trustees Limited (GSK Trust).
- Beneficiaries: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Interest: Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.